Press Release November 20, 2025
Sanofi Wins The 2025 Prix Galien Canada Innovative Product Award
The HRF proudly congratulates Sanofi, the recipient of the 2025 Prix Galien Canada Innovative Product Award! Ottawa, November 20, 2025 […]
Awards
/
The Prix Galien Canada – Product Innovation Award
Presented to a drug that has made the most significant overall contribution to patient care in Canada.
Overview
The Prix Galien Canada – Innovative Product Award is presented every year to the company that has developed a drug product launched on the Canadian market and judged by the Jury to have made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits and innovation.
Call for submissions for the 2025 Prix Galien Canada Innovative Product Award is now closed.
Submission
The Prix Galien Canada – Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.
- The product is considered a “break-through” rather than a derivative of an already existing agent
- The product has made a most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits, and innovation
- The product has a major impact on standards of care
If applicable, the candidate will detail the Canadian contribution to the discovery and/or development of the product and to the contribution to publications related to the product.
Eligibility
For the purpose of Prix Galien Canada, the Jury will use the definition of “drug” in the Food and Drug Act. “Drug” includes any substance or mixture of substances manufactured, sold or represented for use in:
- The diagnosis treatment, mitigation or prevention of a disease, a disorder, an abnormal physical state or the symptoms thereof, in humans and animals;
- Restoring, correcting or modifying organic functions in humans or animals;
- Disinfection in premises in which food is manufactured, prepared or kept.
It must be stressed that to be considered, the drug product must bear a Drug Identification Number (D.I.N.)
Prix Galien Canada guarantees that all information will be held in strict confidentiality and will be available only to parties involved in the adjudication of the award.
Jury
The Jury of the Prix Galien Canada is composed of eminent specialists involved in the sphere of Canadian and Pharmaceutical Research. The Jury is completely independent and its decisions are final.
Dr. Ernesto L. Schiffrin – Chair of the Jury
Distinguished James McGill Professor, Department of Medicine, McGill University,
Director, Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research,
Director, Cardiovascular Prevention Centre and
Physician-in-Chief Emeritus, Sir Mortimer B. Davis-Jewish General Hospital
Dr. Brian O’Rourke
Chair, HTA Steering Committee, Centre for Innovation in Regulatory Science (CIRS)
Member of the Scientific Advisory Council, Centre for Innovation in Regulatory Science (CIRS)
President, Professional Society for Health Economics and Outcomes Research (ISPOR)
Colonel Commandant (Honorary), Royal Canadian Medical Service
Emeritus Member, Canadian Health Leadership Network
Dr. Jill M. Sanders Award of Excellence in Health Technology Assessment
Former President and CEO, CADTH
Dr. Grégoire Leclair
Faculty Secretary, Full Professor
Director, Platform of Biopharmacy
Former Head of Graduate Programs in Drug Development
Faculty of Pharmacy, Université de Montréal
GSK/CSPS Early Career Award
Dr. Kishor M. Wasan
Kishor M. Wasan, R.Ph., Ph.D., FAAPS, FCAHS, FCSPS
Fellow Canadian Academic of Health Sciences
Fellow, American Association of Pharmaceutical Sciences
Distinguished University Scholar & Adjunct Professor
Co-Director/Co-Founder, Neglected Global Diseases Initiative-UBC
Department of Urologic Sciences Faculty of Medicine The University of British Columbia
Chief Medical and Scientific Officer, Skymount Medical US Inc.
Former Dean and Retired Professor, University of Saskatchewan
Dr. Don Weaver
Neurologist and medicinal chemist at the Krembil Research Institute, University Health Network, University of Toronto
Queen’s University
Dalhousie University
PhD in organic chemistry
Co-founder, Neurochem Inc. and Treventis Corp.
His research is focused on the design and development of new chemical entities for the treatment of Alzheimer’s disease
Previous winner of the Prix Galien Canada prize
Laureates
2025
Sanofi
Beyfortus (nirsevimab)
2024
Bristol-Myers Squibb Canada, Co.
CAMZYOS™ (mavacamten)
2023
Pfizer-BioNTech
Comirnaty (COVID-19 Vaccine, mRNA)
2022
Takeda Canada Inc.
Takhzyro (lanedelumab injection)
2020
Alnylam Pharmaceuticals and Medicago
Patisiran (ONPATTRO)
2019
GSK
Dr. Susan George, Dr. Brian O’Dowd, Dr. Gregory A. Demopulos, Dr. George A. Gaitanaris, Dr. Alexander Gragerov
SHINGRIX (Recombinant Zoster Vaccine)
2018
Novartis Pharmaceuticals Canada Inc.
SACUBITRIL/VALSARTAN (Entresto)
2017
Merck Canada
Dr. Ernesto Schiffrin (McGill University)
KEYTRUDA (pembrolizumab)
2016
Gilead Sciences Canada and Takeda Canada
Dr. Philip F. Halloran OC, MD, PhD, FRCPC, FRSC
HARVONI (Sofosbuvir/Ledipasvir) Gilead Sciences Canada
ENTYVIO (Vedolizumab) Takeda Canada
2015
Boehringer-Ingelheim Canada
Dr. John Kelton, Dr. Theodore Warkentin
Afatinib (Giotrif)
2014
Roche and InterMune Canada
Dr. Brett Finlay (University of British Columbia)
PIRFENIDONE (ESBRIET)
2013
Bristol Myers Squibb Canada
Dr. Francis Allan Plummer (University of Manitoba)
YERVOY (IPILIMUMAB)
2012
Vertex Canada Ltd and Merck Canada Inc.
Dr. Robert E. W. Hancock (University of British Columbia)
INCIVEK (TELAPREVIR) Vertex Canada
VICTRELIS (BOCEPRIVIR) Merck Canada Ltd.
2011
Boehringer Ingelheim Canada
Dr. Pieter R. Cullis (University of British Columbia)
PRADAX
2010
Janssen-Ortho
Dr. Julio S. G. Montaner (BC Center for Excellence in HIV/AIDS)
STELARA
2009
Pfizer Canada inc.
Dr. Donald F. Weaver (University of Dalhousie)
CHAMPIX
2008
Merck Frosst Canada
Dr. Daniel J. Drucker (University of Toronto)
GARDASIL
2007
Dr. Michael Hayden (University of British Columbia)
2006
Dr. Harold Jennings (National Research Council Canada)
2005
Dr. Lorne Babiuk (University of Sakatchewan)
2004
Boehringer Ingelheim Canada
Dr. Paul Armstrong (Faculty of medicine, University of Alberta)
SPIRIVA
2003
Novartis Pharma Canada
Dr. Mark A. Wainberg (Jewish General Hospital – Sir Mortimer B. Davis)
GLEEVEC
2002
Wyeth-Ayerst Canada
Drs. Julia Levy and David Dolphin (University Of British Columbia) and (Ex Aequo) Dr Anthony J. Pawson (University Of Toronto)
ENBREL
2001
Pfizer
Dr. Salim Yusuf (Research Centre of the Hamilton Civic Hospital)
VIAGRA
2000
Merck Frosst Canada
Montelukast Sodium Research Team
SINGULAIR
1999
Parke-Davis Canada
Dr. Jack Hirsh (Research Centre of the Hamilton Civic Hospital)
LIPITOR
1998
Merck Frosst Canada
Drs. Lorne Tyrrell and Morris Robins (University Of Edmonton, Alberta)
FOSAMAX
1997
Discovered by BioChem Pharma et développé par Glaxo Wellcome
Drs. Serge Gauthier, Judes Poirier and Rémi Quirion (Mcgill University and Research Centre of the Douglas Hospital)
3TC
1996
Marion Merrell Dow
Antiviral Compounds Research Team (Biochem Pharma)
SABRIL
1995
Janssen Pharmaceutical
Dr. Peter Schiller (IRCM)
RISPERDAL
1994
Glaxo Canada
Drs. Philip Seeman, Hyman Niznik and Hubert Van Tol (University Of Toronto)
IMMITREX
Contact
Prix Galien Canada
Health Research Foundation (HRF) of Innovative Medicines Canada
55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5
Wilma Deen, Executive Director, Health Research Foundation (HRF)
wdeen@imc-mnc.ca
International Contact:
secretarygeneral@prixgalien.com
